Ozempic is a prescription medication containing semaglutide, a drug that mimics a natural gut hormone to lower blood sugar, reduce appetite, and protect against cardiovascular problems. It belongs to a class of drugs called GLP-1 receptor agonists, and it’s FDA-approved specifically for adults with type 2 diabetes. While it’s widely associated with weight loss, Ozempic is not approved as a weight loss drug. That distinction belongs to Wegovy, a higher-dose version of the same molecule.
How Ozempic Works in the Body
Your gut naturally releases a hormone called GLP-1 after you eat. This hormone triggers insulin release, suppresses appetite, and slows digestion. Semaglutide is a synthetic version of that hormone, engineered to last much longer in the body so a single weekly dose keeps working for days.
Ozempic acts on three systems simultaneously. In the pancreas, it boosts insulin secretion, but only when blood sugar is actually elevated. This glucose-dependent mechanism means it’s far less likely to cause dangerously low blood sugar than older diabetes drugs. It also suppresses glucagon, a hormone that tells the liver to release stored sugar into the bloodstream. The combined effect brings blood sugar down from both directions: more sugar pulled out of the blood by insulin, less sugar dumped in by the liver.
In the stomach, semaglutide slows the rate at which food moves into the small intestine. This delayed gastric emptying keeps you feeling full longer after meals and reduces the blood sugar spike that normally follows eating. In the brain, it activates fullness signals that reduce appetite and food intake overall. These overlapping effects explain why people on Ozempic consistently lose weight even though the drug is prescribed for blood sugar control.
What Ozempic Is Approved to Treat
The FDA has approved Ozempic for three specific uses in adults, all tied to type 2 diabetes:
- Blood sugar management: As an add-on to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- Cardiovascular protection: To reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and established heart disease.
- Kidney protection: To reduce the risk of kidney failure, worsening kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
The cardiovascular and kidney benefits go beyond blood sugar control. They represent independent protective effects that make Ozempic more than just a diabetes medication for people who qualify.
How Ozempic Differs From Wegovy
Ozempic and Wegovy contain the same active ingredient, semaglutide, made by the same manufacturer. The key differences are the approved uses and the dosing.
Ozempic is approved for type 2 diabetes. Its maximum dose is 2 mg per week. Wegovy is approved for weight management in adults and children 12 and older with obesity, or in adults who are overweight with at least one weight-related condition like high blood pressure. Wegovy’s maximum dose reaches 2.4 mg per week. Wegovy also carries approvals for cardiovascular risk reduction in people with obesity and for a form of fatty liver disease called MASH.
Both drugs come as prefilled injection pens, but Ozempic pens contain multiple doses while Wegovy pens are single-use. If your doctor prescribes semaglutide primarily for weight loss rather than diabetes, the prescription would typically be written for Wegovy, not Ozempic, though off-label use of Ozempic for weight management is common.
Dosing Schedule
Ozempic is injected once a week, on the same day each week, in the abdomen, thigh, or upper arm. The dose increases gradually over several months to reduce side effects. You start at 0.25 mg weekly for the first four weeks. That starting dose isn’t meant to control blood sugar; it just lets your body adjust. After four weeks, the dose increases to 0.5 mg. If blood sugar still needs better control, your doctor may raise it to 1 mg and eventually to the maximum of 2 mg.
Ozempic is also available as an oral pill, with its own separate dosing tiers. The injection remains the more commonly prescribed form.
Common Side Effects
Roughly half of people taking GLP-1 drugs like Ozempic experience gastrointestinal side effects. These are typically mild to moderate and include nausea, vomiting, diarrhea, and constipation. Nausea is the most frequently reported complaint, and it tends to be worst during dose increases. For most people, these effects ease as the body adjusts over several weeks.
The gradual dose escalation schedule exists specifically to minimize these problems. Eating smaller meals, avoiding high-fat foods, and staying hydrated can also help. Some people find the nausea manageable from the start; others need more time at each dose level before moving up.
Serious Risks to Know About
Ozempic carries a boxed warning, the FDA’s most prominent safety alert, regarding thyroid tumors. In animal studies, semaglutide caused thyroid tumors including a type called medullary thyroid carcinoma. It’s unknown whether this risk applies to humans, but as a precaution, Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a genetic condition called Multiple Endocrine Neoplasia syndrome type 2.
Pancreatitis (inflammation of the pancreas) is another known risk. Symptoms include severe abdominal pain that may radiate to the back, often accompanied by vomiting. This is uncommon but requires immediate medical attention.
People with diabetic retinopathy should be aware of a paradoxical risk: rapid improvements in blood sugar can temporarily worsen eye disease. Clinical trial data from the SUSTAIN 6 trial showed a higher rate of retinal complications in semaglutide users, consistent with a well-documented pattern where 10% to 20% of patients experience worsening eye disease within three to six months of a sudden drop in blood sugar. The risk is highest for those who already have advanced retinopathy. If you have diabetes-related eye disease, your doctor will likely monitor your eyes more closely after starting treatment.
Cost and Insurance Coverage
Ozempic pricing varies significantly depending on insurance status. For commercially insured patients with coverage for Ozempic, a manufacturer savings card can bring the copay down to as little as $25 per month for up to 48 months.
Without insurance, costs are considerably higher. New patients without coverage pay around $199 per month for the lower-dose pen (0.25 mg or 0.5 mg). Existing patients on maintenance doses pay $349 per month for the 0.5 mg or 1 mg pen, and $499 per month for the 2 mg pen. The oral pill version ranges from $149 to $299 per month depending on dose and patient status.
Insurance coverage is not guaranteed. Many plans require prior authorization, meaning your doctor needs to document that you meet specific criteria before the insurer will approve the prescription. Some plans also have step therapy requirements, which means you may need to try older, less expensive diabetes medications first. Coverage depends entirely on your plan’s formulary, so contacting your insurer directly is the only way to know what you’ll pay.